Manipulation Increases Susceptibility of Triple-Negative Breast Cancer to Conventional Therapy

Share this content:
Triple-negative breast cancer is typically less responsive to existing treatments.
Triple-negative breast cancer is typically less responsive to existing treatments.

Researchers at Howard University report that manipulating triple-negative breast cancer cells so they re-express estrogen receptors may be possible, making this type of breast cancer vulnerable to conventional anti-estrogen therapy. Experiments using cell cultures suggest the approach represents an exciting new lead in the fight against triple-negative breast cancer (TNBC) with a new class of compounds.

Most breast cancers are fueled by estrogen, progesterone, or HER2 receptors. However, as many as 20% of breast cancers are negative for all 3 receptors. Triple-negative breast cancer is often more aggressive than other types of breast cancer and is less responsive to existing treatments. Therefore, new treatment options are urgently needed.

In a poster presentation at the American Society for Pharmacology and Experimental Therapeutics 2017 Annual Meeting, Anastasia Robinson, of Howard University, presented findings that suggest triple-negative breast cancers could be made susceptible to anti-estrogen therapy through prior systemic treatment.

Robinson's laboratory developed a novel dichloro-naphthoquinone analog (DCNQ) that is associated with marked antitumorigenic activities and significantly inhibits mitogen activated kinase (MAPK) signaling. The latest round of testing demonstrated this novel compound may offer a model for treating triple-negative breast cancers. 


1. Reversal of the ERα negative receptor in human breast cancer cells by dichloro-napthoquinone analog. Poster presented at: American Society for Pharmacology and Experimental Therapeutics Annual Meeting at EB 2017; April 22-26, 2017; Chicago, IL. 

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs